carbon monoxide has been researched along with pirfenidone in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Arita, M; Fukuda, Y; Hashimoto, T; Ishida, T; Ito, A; Ito, I; Iwasaku, M; Konishi, S; Kourogi, Y; Kunimasa, K; Masuda, G; Nishiyama, A; Tachibana, H; Takaiwa, T; Tanaka, M; Tokioka, F; Tsubouchi, K; Watanabe, N; Yoshioka, H | 1 |
| Bi, Y; Chowdhury, BA; Karimi-Shah, BA; Paterniti, MO; Rekić, D; Wang, Y | 1 |
| Albera, C; Behr, J; Chou, W; Costabel, U; Kirchgaessler, KU; Limb, SL; Morgenthien, E; Nathan, SD; Noble, PW; Stauffer, JL; Wuyts, WA | 1 |
| Bacchi Reggiani, ML; Bandelli, G; Bassi, I; Betti, S; Carpano, M; Cerri, S; Clini, E; Donatelli, P; Garuti, M; Guerrieri, A; Luppi, F; Monari, M; Nava, S; Tonelli, R | 1 |
| Buendía-Roldan, I; Castillo-Castillo, K; Castillo-Pedroza, J; Estrada, A; Gaxiola, M; Mateos-Toledo, H; Mejía-Ávila, M; Mejía-Hurtado, JG; Rodríguez-Barreto, Ó; Rojas-Serrano, J; Selman, M | 1 |
| Fang, C; Ferianc, M; Guo, J; Huang, H; Xu, Z | 1 |
| Bonella, F; Kreuter, M; Li, X; Oltmanns, U; Peng, S; Shi, H; Wei, L; Yin, D | 1 |
| Chang, J; Jung, JY; Kang, YA; Kim, SY; Kim, YS; Lee, SH; Park, MS; Song, MJ | 1 |
| Cho, YJ; Kim, HJ; Kim, TH; Kim, YW; Kwon, BS; Lee, CT; Lee, JH; Lee, YJ; Lim, SY; Park, JS; Shin, YY; Song, MJ | 1 |
1 review(s) available for carbon monoxide and pirfenidone
| Article | Year |
|---|---|
Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis.
Topics: Acetylcysteine; Administration, Inhalation; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Drug Therapy, Combination; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity | 2020 |
2 trial(s) available for carbon monoxide and pirfenidone
| Article | Year |
|---|---|
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Studies; Dyspnea; Exercise Tolerance; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Mortality; Placebos; Pulmonary Diffusing Capacity; Pyridones; Respiratory Function Tests; Treatment Outcome; Vital Capacity | 2019 |
An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis.
Topics: Adult; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Carbon Monoxide; Double-Blind Method; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Lung; Male; Middle Aged; Prednisone; Prospective Studies; Pyridones; Quality of Life; Treatment Outcome; Vital Capacity | 2020 |
6 other study(ies) available for carbon monoxide and pirfenidone
| Article | Year |
|---|---|
Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Carbon Monoxide; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Predictive Value of Tests; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity | 2015 |
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Multivariate Analysis; Pyridones; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vital Capacity | 2017 |
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.
Topics: Carbon Monoxide; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Time Factors; Vital Capacity | 2019 |
Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Carbon Monoxide; China; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vital Capacity | 2020 |
Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antineutrophil Cytoplasmic; Carbon Monoxide; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pulmonary Diffusing Capacity; Pyridones; Republic of Korea; Retrospective Studies; Treatment Outcome; Vital Capacity | 2021 |
Impact of body weight change on clinical outcomes in patients with idiopathic pulmonary fibrosis receiving pirfenidone.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Carbon Monoxide; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity; Weight Loss | 2022 |